Careers  |  Sign In  |  Register

FDA Okays Another Immunotherapy Plus TKI for Advanced RCC

New Indication

The US Food and Drug Administration (FDA) has approved the immunotherapy avelumab in combination with the tyrosine kinase inhibitor axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The approval is based on the results of the JAVELIN-Renal 101 study.

Learn more by clicking here.